Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients

被引：0
|
作者：
M Wilbaux
E Hénin
A Oza
O Colomban
E Pujade-Lauraine
G Freyer
M Tod
B You
机构：
[1] EMR 3738,Department of Medical Oncology and Hematology
[2] Ciblage Thérapeutique en Oncologie,undefined
[3] Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux,undefined
[4] Université Claude Bernard Lyon 1,undefined
[5] Princess Margaret Hospital,undefined
[6] University Health Network,undefined
[7] Hôpital Hôtel Dieu,undefined
[8] Place du Parvis Notre-Dame,undefined
[9] Service d’Oncologie Médicale,undefined
[10] Investigational Center for Treatments in Oncology and Hematology of Lyon,undefined
[11] Centre Hospitalier Lyon-Sud,undefined
[12] Hospices Civils de Lyon,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
CA-125 kinetics; ovarian epithelial cancer; mathematical modelling; K–PD modelling; tumour size prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1517 / 1524
页数：7
相关论文
共 50 条
  • [41] The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer
    Deng, XH
    Hogdall, EVS
    Hogdall, CK
    Norgaard-Pedersen, B
    Jorgensen, M
    Nielsen, H
    Engelholm, SAA
    GYNECOLOGIC ONCOLOGY, 2000, 79 (03) : 416 - 419
  • [42] A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer
    Chiang, An Jen
    Chen, Jiabin
    Chung, Yu-He
    Huang, Huan-Jung
    Liou, Wen Shiung
    Chang, Chung
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2014, 25 (01) : 51 - 57
  • [43] THE OVARIAN-CANCER ASSOCIATED ANTIGEN CA-125 IN PATIENTS WITH PLEURAL EFFUSIONS
    LINDGREN, J
    KUUSELA, P
    HELLSTROM, PE
    PETTERSSON, T
    KLOCKARS, M
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (04): : 737 - 739
  • [44] Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer
    Nielsen, HA
    Nielsen, D
    Engelholm, SA
    GYNECOLOGIC ONCOLOGY, 2000, 77 (03) : 383 - 388
  • [45] TUMOR-ASSOCIATED ANTIGEN CA-125 IN PATIENTS WITH OVARIAN-CANCER
    HEINONEN, PK
    TONTTI, K
    KOIVULA, T
    PYSTYNEN, P
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1985, 92 (05): : 528 - 531
  • [46] CLINICAL RELEVANCE OF THE CA-125 ASSAY IN MONITORING OF OVARIAN-CANCER PATIENTS
    HISING, C
    ANJEGARD, IM
    EINHORN, N
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (02): : 111 - 114
  • [47] Elevated ovarian cancer marker (CA-125) in cirrhotic patients with intractable ascites
    Zamir, D
    Jarchovsky, J
    Singer, C
    Weiner, P
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1998, 27 (02) : 154 - 155
  • [48] IMMUNOSUPPRESSIVE ACIDIC PROTEIN AND CA-125 LEVELS IN PATIENTS WITH OVARIAN-CANCER
    CASTELLI, M
    BATTAGLIA, F
    SCAMBIA, G
    PANICI, PB
    FERRANDINA, G
    MILEO, AM
    MANCUSO, S
    FERRINI, U
    ONCOLOGY, 1991, 48 (01) : 13 - 17
  • [49] VALUE OF TUMOR-MARKER CA-125 AS A PROGNOSTIC PARAMETER IN RECURRENT OVARIAN-CANCER
    BAUMGARTNER, L
    MEIER, W
    STIEBER, P
    FATEHMOGHADAM, A
    EIERMANN, W
    HEPP, H
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 959 - 962
  • [50] Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer
    Armstrong, Amy
    Otvos, Balint
    Singh, Sareena
    Debernardo, Robert
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 503 - 507
12345